

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	PCT/CA2004/001484
Filing Date	August 11 2004
First Named Inventor	James B. Jaquith
Art Unit	
Examiner Name	
Attorney Docket Number	126-PCT2-US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 ^o
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
MA		CA 2,409,355	11-22-2001	Fallis et al		
		WO 99/47518 A	09-23-1999	Hoffman-LaRoche		
		WO 98/04551 A	02-05-1998	Hoffman-LaRoche		

Date
Considered

8/31/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	PCT/CA2004/001484
		Filing Date	August 11 2004
		First Named Inventor	James B. Jaquith
		Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	126-PCT2-US


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	1	DAVIS, P.D., et al. "Inhibitors of Protein Kinase C.I. 2,3-Bisarylmalimides". Journal of Medicinal Chemistry, vol. 35, no. 1, 10 January 1992, pages 177-184.	
L	2	DAVIS, P.D., et al. "A Mild Conversion of Maleic Anhydrides into Maleimides", Tetrahedron Letters, vol.31, no. 36, 1990, pages 5201-5204	

Examiner Signature		Date Considered	8/31/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO-1449			Complete if Known	
INFORMATION DISCLOSURE STATEMENT			Application No.:	10/637,599
			Filing Date:	August 11, 2003
			First Named Inventor:	James B. JAQUITH, et al.
			Group Art Unit:	1625
			Examiner Name:	Charanjit AULAKH
Sheet	1	of	Attorney Docket No.:	PAT 209AW-2



U.S. PATENT DOCUMENTS:

Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RA		5,057,614	10-15-1991	Davis et al.	example 46, column 23, 57-58

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T Is attached Check if English Translation
RA		WO 01/87887	11-22-2001	Aegera Therapeutics Inc.	entire document	<input checked="" type="checkbox"/>
L		WO 99/47518	09-23-1999	F. Hoffmann-La Roche AG	claims; examples	<input type="checkbox"/>
L		WO 98/04551	02-05-1998	F. Hoffmann-La Roche AG	claims; examples	<input type="checkbox"/>

OTHER DOCUMENTS

RA		Davis et al., "Inhibitors of Protein Kinase C.I. 2,3-Bisarylmalimides", pp. 177-184, J. Med. Chem., 35, 1992.
L		Davis et al., "A Mild Conversion of Maleic Anhydrides Into Maleimides", pp. 5201-5204, Tetrahedron Letters, Vol. 31, No. 36, 1990.

Examiner Signature:	Date Considered: 8/31/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			Complete if Known		
			Application No.:	10/637,599	
			Filing Date:	August 11, 2003	
			First Named Inventor:	James B. JAQUITH et al.	
			Group Art Unit:	1614	
Examiner Name:					
Sheet	1	of	3	Attorney Docket No.:	PAT 209AW-2

U.S. PATENT DOCUMENTS


Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Rut ↓		5,883,114	03-16-1999	Kleinschroth et al.	claims; examples
		5,859,261	01-12-1999	Faul et al.	preparation 2
		5,405,864	04-11-1995	Broka	column 1, line 10-column 2, line 10; claims; examples

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
Rut ↓		EP 0 328 026	08-16-1989	F. Hoffman-La Roche	page 9, line 11-line 58; claims; example 46	✓	
		WO 99/47518	09-23-1999	F. Hoffman-La Roche	claims; examples		
		WO 98/04551	02-05-1998	F. Hoffman-La Roche	page 2, paragraph 2; claims; examples		

OTHER DOCUMENTS

Rut ↓	Gribble, G. W. et al., Studies in Natural Products Chemistry, 1993, 12, pp. 365-409
	Wood, J. L. et al., J. Am. Chem. Soc., 1997, 119, pp. 9641-9651
	Link et al., J. Am. Chem. Soc., 1996, 118, pp. 2825-2842
	Bergman, J. et al., Tetrahedron, 55, 1999, pp. 2363-2370
	Janosik et al., Tetrahedron, 55, 1999, pp. 2371-2380
	Nakanishi, J. Antibiotics, 1986, 39, pp. 1066-1071
↓	Toledo and Lydon, Structure, 1997, 5, No. 12, pp. 1551-1556

Examiner Signature: 	Date Considered: 8/31/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Complete if Known	
				Application No.: 10/637,599	
				Filing Date: August 11, 2003	
				First Named Inventor: James B. JAQUITH et al.	
				Group Art Unit: 1614	
Examiner Name:				Attorney Docket No.: PAT 209AW-2	
Sheet	2	of	3		

U.S. PATENT DOCUMENTS


Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ✓	Check if English Translation is attached
KY		WO 99/47522	09-23-1999	University of British Columbia	claims; examples		
		EP 0 397 060	11-14-1990	Gödecke	claim 5		
✓		WO 97/34890	09-25-1997	Eli Lilly & Co.	page 27; preparation 3.		

OTHER DOCUMENTS

KH		Davis, P.D., et al., "Inhibitors of Protein Kinase C.I. 2,3-Bisarylmaleimides", Journal of Medicinal Chemistry, vol. 35, no. 1, January 10, 1992, pages 177-184, XP002028954
un		Davis, P.D., et al., "A Mild Conversion of Maleic Anhydrides into Maleimides" Tetrahedron Letters, vol. 31, no. 36, 1990, pages 5201-5204, XP001021319

Examiner Signature: 	Date Considered: 8/3/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449		Complete If Known			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Application No.:	10/637,588		
		Filing Date:	August 11, 2003		
		First Named Inventor:	James B. JAQUITH et al.		
		Group Art Unit:	1614		
		Examiner Name:			
Sheet	3	of	3	Attorney Docket No.:	PAT 209AW-2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
<i>hst</i>		EP 0 540 956	05-12-1993	F. Hoffman-La Roche	claims; examples 14, 19	✓	
<i>L</i>		DE 40 05 970	08-29-1991	Boehringer Mannheim	page 8, line 20-line 39; claims; examples 1, 2		
		WO 99/42100	08-26-1999	Sagami Chemical Research Centre	claims		

OTHER DOCUMENTS

Examiner Signature: <i>[Signature]</i>	Date Considered: <i>8/31/07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449		Complete if Known			
INFORMATION DISCLOSURE STATEMENT		Application No.:			
		Filing Date:	August 11, 2003		
		First Named Inventor:	James B. JAQUITH et al.		
		Group Art Unit:			
		Examiner Name:			
Sheet	1	of	3	Attorney Docket No.:	PAT 209AW-2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KJ		5,919,912	07-06-1999	Korneluk et al.	
		6,013,646	01-11-2000	Roder et al.	
		5,756,494	05-26-1998	Lewis et al.	
		5,741,808	04-21-1998	Lewis et al.	
		5,621,101	04-15-1997	Lewis et al.	
		4,923,986	05-08-1990	Murakata et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
KJ		WO 96/31515	10-10-1996	Cephalon, Inc.			
		WO 97/46565	12-11-1997	Cephalon, Inc.			
		WO 97/49406	12-31-1997	Engber et al.			

OTHER DOCUMENTS

KJ		Kitada, S. et al., "Blood", 2000, 96, 393
		Iqbal, K. et al., FEBS Lett., 1994, 349, 104
		Garver, T.D. et al., J. Neurosci. Res., 1996, 44, 12
		Kaneko, et al., J. Med. Chem., 1997, 40, 1863
		Maroney, A.C. et al., J. Neurosci., 1998, 18, 104
		Sancelme, et al., J. Antibiotics, 1994, 47, 792
		Hachisu et al., Life Sciences, 1989, 44, 1351

Examiner Signature: <i>[Signature]</i>	Date Considered: 8/31/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT				Complete if Known:	
				Application No.:	
				Filing Date:	August 11, 2003
				First Named Inventor:	James B. JAQUITH et al.
				Group Art Unit:	
Examiner Name:					
Sheet	2	of	3	Attorney Docket No.:	PAT 209AW-2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite. No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JH L		4,877,776	10-31-1989	Murakata et al.	
		5,919,946	07-06-1999	Faul et al.	
		6,037,475	03-14-2000	Faul et al.	
		6,020,127	02-01-2000	MacKenzie et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite. No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
JH L		WO 95/07911	03-23-1995	Cephalon, Inc.			
		WO 94/02488	02-03-1994	Cephalon, Inc.			
		EP 0 323 171	07-05-1989	Kyowa Hakko Kogyo Co., Ltd.			

OTHER DOCUMENTS

JH L	Bit et al., J. Med. Chem., 1993, 36, 21
	Bergman et al., Tetrahedron Lett., 1987, 28, 4441
	Faul, M.M. et al., Tetrahedron Lett., 1999, 40, 1109
	Bradshaw, D. et al., Agents and Actions, 1993, 38, 137
	Khusel, B. & Hefti, F.J., Neurochem., 1992, 59, 1987
	Xu, D.G. et al., Nature Medicine, 1997, 3, 997

Examiner Signature:	<i>[Signature]</i>	Date Considered:	8/31/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT				Complete if Known	
				Application No.:	
				Filing Date:	August 11, 2003
				First Named Inventor:	James B. JAQUITH et al.
				Group Art Unit:	
Examiner Name:					
Sheet	3	of	3	Attorney Docket No.: PAT. 209AW-2	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
<i>me</i>		EP 0 643 966	03-22-1995	Kyowa Hakko Kogyo Kabushiki Kaisha			
<i>z</i>		WO 94/27982	12-08-1994	Cephalon, Inc.			

OTHER DOCUMENTS

<i>me</i>		Uzawa, et al., Cancer Genet Cytogenet, 1998, 11, 125
<i>z</i>		Chan, S.L., Mattson, M.P., J. Neurosci. Res., 1999, 58, 167
<i>z</i>		Kanfer, J.N. et al., Neurochem Res., 1999, 24, 1621
<i>z</i>		Suzuki, A. et al., Exp. Cel. Res., 1997, 233, 41

Examiner Signature: <i>[Signature]</i>	Date Considered: <i>8/31/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.	